ClinicalTrials.gg
WithdrawnNCT02999906Updated Nov 1, 2017

Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

A Phase 3 interventional study of Oral Treprostinil and Placebo in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Withdrawn. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2017-11-01.

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

Why this study was withdrawn
For business reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
38th of 44
0 · median 32
Started
2017
with 3 others
Phase 3
14 of 44
1 open now
Registered
29th of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 38th largest by enrollment, is one of 4 that started in 2017, is one of 14 in phase 3, and was the 29th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This is a multicenter, randomized (2:1 oral treprostinil: placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are currently receiving background dual therapy (ambrisentan, tadalafil) for at least 30 days at randomization for their PAH. Once randomized, subjects will return for 5 study visits up to Week 28 during the blinded period. After the Week 28 Visit, eligible subjects will transition to the open-label period of the study for up to 20 weeks.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • PAH
  • Oral Treprostinil
  • dual therapy
  • 6 Minute Walk Test
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Between 18 and 79 years of age, inclusive
  2. PAH that is idiopathic / heritable, PAH associated with connective tissue disease, infection, repaired congenital systemic-to-pulmonary shunts (repaired > 1 year), or appetite suppressant / toxin use
  3. Receiving dual therapy (ambrisentan and tadalafil)
  4. Previous testing (e.g. right heart catheterization, echocardiography) consistent with diagnosis of PAH

Exclusion criteria

Exclusion Criteria:

  1. Nursing or pregnant
  2. PAH due to conditions other than noted in the above inclusion criteria
  3. Received PAH-specific drug therapy for >2 years
  4. History of uncontrolled sleep apnea, severe liver disease, severe renal impairment, left sided heart disease, uncontrolled systemic hypertension
  5. Participated in an drug or device study within 90 days prior to signing consent.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo (sugar pill)

    Drug: Placebo

  • Active comparator
    Active

    Oral treprostinil sustained release tablet

    Drug: Oral Treprostinil

Interventions

  • Sustained release oral tablets for three times daily administration

    Also known as: treprostinil diethanolamine

  • DrugPlacebo

    Placebo (sugar pill) for three times daily oral administration

    Also known as: matching placebo (sugar pill)

06

What researchers measure

Primary outcomes

  1. Change in 6-Minute Walk Distance (6MWD)

    Time frame: Baseline to Week 28

Secondary outcomes

  1. Compare the effects of triple therapy versus dual therapy on the time to clinical worsening

    clinical worsening is defined by 1 of the following: * Death (all causes) * Hospitalization due to worsening PAH * Initiation of long-term parenteral therapy * Disease progression * Unsatisfactory long-term clinical response

    Time frame: Baseline to Week 28

  2. Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations From Baseline to Week 28

    The level of this biomarker of the (NT-proBNP) serum concentration will be assessed to compare the severity of heart failure at Baseline and Week 28.

    Time frame: Baseline to week 28

  3. Number of Participants with a Change From Baseline World Health Organization (WHO) Functional Classification at Week 28.

    The WHO Functional Class of pulmonary hypertension is a physical activity rating scale as follows: Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Inability to carry out any physical activity without symptoms.

    Time frame: Baseline to week 28

  4. Change in Quality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) From Baseline to Week 28.

    The CAMPHOR is a health related quality of life instrument validated for pulmonary hypertension that assesses impairment (symptoms), disability (activities) and quality of life. The questionnaire is divided into three sections; Symptoms (Scores 025; high scores indicate more symptoms), Activity (Score 030; low score indicates good functioning) and Quality of Life (025; high scores indicate poor QoL). The sum of these scores equates to the Total score (080). In the CAMPHOR scores, lower scores indicate improvements.

    Time frame: Baseline to week 28

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2017; primary completion for Dec 2021, 50 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2016
First posted
Dec 21, 2016
StartEst.
Oct 2017
Primary completionEst.
Dec 2021
CompletionEst.
Jun 2022
Last update
Nov 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02999906
Responsible party
Sponsor
First posted
Dec 21, 2016
Start date
Oct 2017 (estimated)
Primary completion
Dec 2021 (estimated)
Completion
Jun 2022 (estimated)
Last update
Nov 1, 2017

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion